Physician experiences with sodium-glucose cotransporter (SGLT2) inhibitors, a new class of medications in type 2 diabetes, and adverse effects

AIM: The primary aim of our study is to identify physicians who have witnessed a complication attributed to sodium-glucose cotransporter (SGLT2) inhibitors. The secondary aim is to determine the type, severity, and setting of the event (inpatient versus outpatient). BACKGROUND: Diabetes is an increa...

Descripción completa

Detalles Bibliográficos
Autores principales: Patakfalvi, Laura, Brazeau, Anne-Sophie, Dasgupta, Kaberi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567894/
https://www.ncbi.nlm.nih.gov/pubmed/30032729
http://dx.doi.org/10.1017/S1463423618000476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567894/
https://www.ncbi.nlm.nih.gov/pubmed/30032729
http://dx.doi.org/10.1017/S1463423618000476

Ejemplares similares